The Technical Advisory Group on SARS-CoV-2 Virus Evolution met today to review what is known about the #COVID19 variant B.1.1.529. They advised WHO that it should be designated a Variant of Concern.
I guess it depends in what is relevant to individual shareholders. If a PI comes away from the meeting and decides to add to their investment based on what they have heard, I would suggest that's important. Past SP performance after an AGM is completely irrelevant.
AZN Covid-19 vaccine showed 74% efficacy in a U.S. clinical trial, and 83.5% efficacy in people 65 years and older. The company expects to file for U.S. approval later this year! CNBC